Histopathological and immunophenotypic features of ipilimumab‐associated colitis compared to ulcerative colitis

Abstract

Ipi-AC is a distinct pathologic entity with notable clinical and histopathological differences compared to UC. These findings provide insights into the pathophysiology of immune-related adverse events (iAEs) from ipilimumab therapy.